WO2002040030A8 - Combination therapy for lowering and controlling intraocular pressure - Google Patents

Combination therapy for lowering and controlling intraocular pressure

Info

Publication number
WO2002040030A8
WO2002040030A8 PCT/US2000/031557 US0031557W WO0240030A8 WO 2002040030 A8 WO2002040030 A8 WO 2002040030A8 US 0031557 W US0031557 W US 0031557W WO 0240030 A8 WO0240030 A8 WO 0240030A8
Authority
WO
WIPO (PCT)
Prior art keywords
lowering
combination therapy
intraocular pressure
controlling intraocular
ocular hypertension
Prior art date
Application number
PCT/US2000/031557
Other languages
French (fr)
Other versions
WO2002040030A1 (en
Inventor
Abbot F Clark
Original Assignee
Alcon Lab Inc
Abbot F Clark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc, Abbot F Clark filed Critical Alcon Lab Inc
Priority to EP00980450A priority Critical patent/EP1341541A4/en
Priority to AU2001217709A priority patent/AU2001217709B2/en
Priority to AU1770901A priority patent/AU1770901A/en
Priority to PCT/US2000/031557 priority patent/WO2002040030A1/en
Priority to CA002428799A priority patent/CA2428799A1/en
Priority to JP2002542403A priority patent/JP2004522711A/en
Publication of WO2002040030A1 publication Critical patent/WO2002040030A1/en
Publication of WO2002040030A8 publication Critical patent/WO2002040030A8/en
Priority to AU2006200143A priority patent/AU2006200143B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Angiostatic agents and another IOP lowering compound are combined in ophthalmic compositions to treat glaucoma and ocular hypertension. Methods for treating glaucoma and ocular hypertension are also disclosed.
PCT/US2000/031557 2000-11-16 2000-11-16 Combination therapy for lowering and controlling intraocular pressure WO2002040030A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP00980450A EP1341541A4 (en) 2000-11-16 2000-11-16 Combination therapy for lowering and controlling intraocular pressure
AU2001217709A AU2001217709B2 (en) 2000-11-16 2000-11-16 Combination therapy for lowering and controlling intraocular pressure
AU1770901A AU1770901A (en) 2000-11-16 2000-11-16 Combination therapy for lowering and controlling intraocular pressure
PCT/US2000/031557 WO2002040030A1 (en) 2000-11-16 2000-11-16 Combination therapy for lowering and controlling intraocular pressure
CA002428799A CA2428799A1 (en) 2000-11-16 2000-11-16 Combination therapy for lowering and controlling intraocular pressure
JP2002542403A JP2004522711A (en) 2000-11-16 2000-11-16 Combination therapy for reducing and controlling intraocular pressure
AU2006200143A AU2006200143B2 (en) 2000-11-16 2006-01-13 Combination therapy for lowering and controlling intraocular pressure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/031557 WO2002040030A1 (en) 2000-11-16 2000-11-16 Combination therapy for lowering and controlling intraocular pressure

Publications (2)

Publication Number Publication Date
WO2002040030A1 WO2002040030A1 (en) 2002-05-23
WO2002040030A8 true WO2002040030A8 (en) 2002-11-07

Family

ID=21742004

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031557 WO2002040030A1 (en) 2000-11-16 2000-11-16 Combination therapy for lowering and controlling intraocular pressure

Country Status (5)

Country Link
EP (1) EP1341541A4 (en)
JP (1) JP2004522711A (en)
AU (2) AU2001217709B2 (en)
CA (1) CA2428799A1 (en)
WO (1) WO2002040030A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
EP1841780B1 (en) 2005-01-10 2011-07-27 Glaxo Group Limited Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
CN108066283B (en) * 2017-12-28 2020-03-24 兆科（广州）眼科药物有限公司 Preparation method of levobetaxolol hydrochloride eye drops

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
WO1987007141A1 (en) * 1986-05-23 1987-12-03 New England Medical Center Hospitals, Inc. Method for treating glaucoma
US4904649A (en) * 1986-05-23 1990-02-27 New England Medical Center Hospitals, Inc. Method and solution for treating glaucoma
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5153192A (en) * 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
CA2425849C (en) * 1991-11-22 2007-02-27 Alcon Laboratories, Inc. Angiostatic steroids
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
ES2203103T3 (en) * 1998-04-07 2004-04-01 Alcon Manufacturing Ltd. GELIFYING OPHTHALMIC COMPOSITIONS CONTAINING XANTANA GUM.
EP1115406A4 (en) * 1998-09-25 2003-03-05 Alcon Lab Inc Sustained release, and comfortable ophthalmic composition and method for ocular therapy

Also Published As

Publication number Publication date
AU1770901A (en) 2002-05-27
CA2428799A1 (en) 2002-05-23
AU2001217709B2 (en) 2005-10-13
EP1341541A4 (en) 2004-11-17
WO2002040030A1 (en) 2002-05-23
JP2004522711A (en) 2004-07-29
EP1341541A1 (en) 2003-09-10

Similar Documents

Publication Publication Date Title
AU2003274734A1 (en) Method and composition containing latanoprost for treating ocular hypertension and glaucoma
MX9702349A (en) Use of 9-deoxy prostaglandin derivatives to treat glaucoma.
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
CA2440764A1 (en) Combination of brimonidine and timolol for topical ophthalmic use
WO2002062385A3 (en) Method to prevent vision loss
CA2582316A1 (en) Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
EP1514548A3 (en) Use of cloprostenol fluprostenol, and their analogues to treat glaucoma and ocular hypertension
CA2315829A1 (en) Angiostatic agents and compositions for controlling ocular hypertension
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2006066103A3 (en) Ophthalmic implant for treatment of glaucoma
WO2003047513A3 (en) Method for treating ocular hypertension
BR0210241A (en) Pyanoindazoles and their use in the treatment of glaucoma
WO2003072066A3 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
CA2505086A1 (en) Ophthalmic compositions for treating ocular hypertension
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004073607A3 (en) Use of steroids to treat ocular disorders
WO2002040030A8 (en) Combination therapy for lowering and controlling intraocular pressure
AU687906B2 (en) Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
WO2001070207A3 (en) 5ht2 agonists for controlling iop and treating glaucoma
EP1251862A4 (en) Ophthalmic compositions for treating ocular hypertension

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN JP MX PL ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AU BR CA CN JP KR MX PL US ZA

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2001217709

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002542403

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2000980450

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2428799

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2000980450

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001217709

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 2000980450

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000980450

Country of ref document: EP